Interventional Cardiology Devices – Market Insights – Latin America

The Latin American IC device market will see strong growth over the forecast period, driven by a rising patient population, the introduction of next-generation devices, and the expanding adoption of complex PCIs. Furthermore, premium-priced advanced technologies—such as lithotripsy balloons, DCBs, and newer-generation stents—are witnessing strong uptake. These innovations are expected to reshape current treatment algorithms, thereby disrupting the dominance of established category leaders.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for IC devices in the Latin American region from 2019 through 2034.

The increasing prevalence of complex PCI cases will drive demand for innovative devices and result in a higher proportion of complex PCIs.

Which factors are contributing to the increasing prevalence of complex CAD cases?

What factors are influencing complex PCI procedure volume growth in the Latin American IC device market?

Despite the increasing prevalence of complex PCIs, what factors are limiting the uptake of innovative devices in the Latin American IC device market?

There is a growing competition in the Latin American IC device market.

What are the future prospects of the companies operating in the market?

Which companies are expected to launch their products in the Latin American IC device market?

Which new competitors are expected to enter this market?

Positive clinical data supporting the use of DCBs and specialty balloons is expected to influence physician practice over the forecast period.

How strongly is favorable clinical data expected to impact the DCB and specialty balloon markets?

How has clinical data impacted major market players in these segments?

What new products and competitors are expected to change market dynamics in these segments?

What is the expected impact of emerging balloon-based technologies such as DCBs?

Device ASP trends will play a significant role in determining market growth through 2034.

How will government-driven pricing pressures and increasing competition affect ASPs?

Which product segments will be the most impacted?

Adoption of some premium-priced products, such as lithotripsy balloons, DCBs, and BRS, will be limited through 2034.

How has the commercialization of the lithotripsy balloons, DCBs, and BRS impacting other competing products?

How are these technologies likely to evolve over the coming years?

New technologies are expected to receive approval in the near future and change the way complex PCIs are diagnosed and treated.

What is the impact of the latest generation of alternative coronary physiology modalities such as resting index or imaging-based FFR_angio and FFR_CT on the patient and procedure in cardiac catheterization labs?

How are novel technologies with improved outcomes performing against the already approved products in the covered markets?

What are the recent events in the advanced diagnostic imaging space? How will these impact the existing players going forward?

How CCTA is expected to impact diagnostic angiography in the coming years?

How are IVUS and OCT competing against the conventional diagnostic angiography techniques? How are clinical trials impacting the use of these products?

How will the emergence of alternative FFR modalities affect the FFR pressure guidewire market?